| Literature DB >> 31136109 |
Rohan Patel1, Samarth Agarwal1, S N Sankhwar1, Apul Goel1, B P Singh1, Manoj Kumar1.
Abstract
OBJECTIVES: To primarily evaluate the functional outcomes of PCNL for bilateral renal calculi/calculi in solitary functioning kidney with Chronic Kidney Disease(CKD). To identify factors affecting the renal replacement therapy following PCNL.Entities:
Keywords: Kidney Diseases; Nephrolithotomy, Percutaneous; Urinary Tract Infections
Mesh:
Substances:
Year: 2019 PMID: 31136109 PMCID: PMC6837603 DOI: 10.1590/S1677-5538.IBJU.2018.0816
Source DB: PubMed Journal: Int Braz J Urol ISSN: 1677-5538 Impact factor: 1.541
Figure 1Comparison of pre op and post op GFR and stage migration.
Univariate analysis of patient and procedure related factors affecting kidney function after PCNL.
| Variable | Group 1(n) | Group 2 (n) | P value |
|---|---|---|---|
| Baseline | 25.65 | 22.44 | 0.20 |
| Follow-up | 29.07 | 20.71 | |
| Age(Mean ± SD)years | 41.6 ± 15.5 | 47.13 ± 18.2 | 0.25 |
| M | 33 | 10 | |
| F | 12 | 5 | |
| Diabetes | 3 | 4 | |
| Hypertension | 7 | 5 | 0.13 |
| Previous open surgery | 7 | 5 | 0.13 |
| Mild to moderate | 60 | 17 | |
| Severe | 9 | 5 | |
| 1-2 | 40 | 13 | |
| 3-4 | 29 | 9 | |
| 1 | 0 | 0 | |
| 2 | 0 | 0 | |
| 3 | 14 | 3 | |
| 4 | 26 | 9 | |
| 5 | 5 | 3 | |
| Single | 33 | 11 | |
| Multiple | 36 | 11 | |
| Supracostal puncture | 20 | 5 | 0.56 |
| <100 min. | 23 | 6 | |
| >100 min. | 46 | 16 | |
| Yes | 10 | 4 | |
| No | 35 | 11 | |
| Yes | 39 | 10 | |
| No | 6 | 5 | |
| Yes | 11 | 9 | |
| No | 34 | 6 | |
| Yes | 3 | 4 | |
| No | 42 | 11 |
Different studies comparing various preop, intra op and post op characteristics.
| Study | Age Mean (SD, range) years | Diabetes | Inclusion criteria (eGFR (mL/min./1.73 m2) | Mean Pre-Op. eGFR (mL/min./1.73 m2) | Mean Operative time Min. (SD,range) | Complication Haemmorhage requiring | Follow up eGFR(mL/min/1.73m2) | Overall change | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Transfusion | Sepsis | ||||||||
| 43.16 | 11.6% | <60/S. Creatinine >2 | 24.9 ± 8.56 | 120.01 (38.24, 60-250) | 26.6% | 5% | 27 | improved | |
| Bilen et al. ( | 53.2 (NR, | 1.62% | <60 | S. Creatinine 1.87 | 101.4 (NR, NR) | 36% | 3% | 48.4 | improved |
| Kurien et al. ( | 52.5 (13, NR) | - | S. Creatinine >1.5 | S. Creatinine 3.2 | NR | 20.5% | 9.9% | 43.3 | improved |
| Akman et al. ( | 54.3 ± 12.1 years | 19.8% | <60 | 44.8 | 65.12 (22.83, NR) | 9.6% | 2.8% | 48 | improved |
| Ozden et al. ( | - | - | <60 | 39.9 | NR | - | - | 51.3 | improved |
| Akdeniz et al. ( | 59.5 (7.85, 39-78) | 11.8% | <60 | 44.8 | NR | 11.8% | NR | 51.8 | improved |
| Sairam et al. ( | - | 18.8% | - | - | 89 (52.3, NR) | - | - | - | improved |
| Kumar et al. ( | 45 (NR, 18-65) | - | s.creat. >4.5 | s.creat. -6.3 | 110 (32,NR) | 20% | 20% | 2.56 (s.creatinine) | improved |